文献速递心脑血管急症消化、代谢与肾脏急症

Lorundrostat 用于未控制高血压及难治性高血压受试者:Launch-HTN 随机临床试验

Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-01
一句话结论在已用2–5种降压药的未控制高血压(含难治性高血压)成人中,加用 lorundrostat 50 mg/d 使第6周自动诊室收缩压较安慰剂多降低9.1 mm Hg(95%CI -13.3至-4.9,P<.001),但低钠血症、高钾血症和肾功能下降更常见。

这项3期随机临床试验在13个国家159个中心纳入1083例已用2–5种降压药仍未控制的高血压成人(含难治性高血压),按1:2:1随机分为50 mg/d lorundrostat用6周后符合预设标准可升至100 mg/d再用6周组(n=270)、50 mg/d lorundrostat用12周组(n=541)和安慰剂组(n=272)。主要终点为第6周自动诊室收缩压变化,合并50 mg组(n=808)较安慰剂组多降低9.1 mm Hg(95%CI -13.3至-4.9,P<.001)。低钠血症、高钾血症和肾功能下降在lorundrostat组更常见,治疗中出现的不良事件发生率49.9%(538/1078),多为轻中度。作者结论认为lorundrostat在未控制高血压(含难治性高血压)成人中降低血压的疗效和安全性得到证实。

要点

  • 已用2–5种降压药的未控制高血压成人中,加用lorundrostat 50 mg/d使第6周自动诊室收缩压较安慰剂多降低9.1 mm Hg(95%CI -13.3至-4.9,P<.001)。
  • 合并50 mg组第6周收缩压最小二乘均值变化-16.9 mm Hg(95%CI -19.0至-14.9),安慰剂组-7.9 mm Hg(95%CI -11.5至-4.2)。
  • 低钠血症、高钾血症和肾功能下降在lorundrostat组较安慰剂更常见。
  • 50 mg组因高钾血症停药2例(0.37%)、因低钠血症停药2例(0.37%)、因肾功能下降停药3例(0.56%);50 mg可升至100 mg组因高钾血症停药1例(0.37%)、因低钠血症停药1例(0.37%)、因肾功能下降停药0例。
  • 治疗中出现的不良事件发生率49.9%(538/1078),多为轻中度。

适用人群与场景

  • 已用2–5种降压药仍未控制的高血压成人,包括难治性高血压患者。
  • 随机时39.9%(432例)使用2种降压药,60.1%(651例)使用3种及以上。
  • 平均年龄61.6岁(SD 10.3岁),女性508例(46.9%),Black或African American 311例(28.7%),White 733例(67.7%),BMI≥30者685例(63.3%)。

诊断标准与关键阈值

  • 从50 mg/d升至100 mg/d的预设标准:收缩压≥130 mm Hg、钾≤4.8 mmol/L、钠≥135 mmol/L、eGFR>45 mL/min/1.73 m2,且eGFR下降<25%。

处置流程与药物剂量

  • 50 mg/d lorundrostat用6周后符合预设标准者升至100 mg/d再用6周(n=270)。
  • 50 mg/d lorundrostat用12周(n=541)。
  • 安慰剂每日用12周(n=272)。

红旗征与不能漏的情况

  • 低钠血症、高钾血症和肾功能下降在lorundrostat组较安慰剂更常见。
  • 50 mg可升至100 mg组因高钾血症停药1例(0.37%)、因低钠血症停药1例(0.37%)、因肾功能下降停药0例。
  • 50 mg组因高钾血症停药2例(0.37%)、因低钠血症停药2例(0.37%)、因肾功能下降停药3例(0.56%)。

研究设计与关键结果

  • 3期随机临床试验,1083例受试者,13个国家159个中心,2023年11月至2024年9月入组,末次随访2025年1月24日。
  • 主要终点:合并50 mg组(n=808)第6周自动诊室收缩压最小二乘均值变化-16.9 mm Hg(95%CI -19.0至-14.9),安慰剂组-7.9 mm Hg(95%CI -11.5至-4.2),最小二乘均值差-9.1 mm Hg(95%CI -13.3至-4.9),P<.001。
  • 治疗中出现的不良事件发生率49.9%(538/1078),多为轻中度。

证据类型、等级与局限

  • 证据类型:3期随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为lorundrostat在未控制高血压(含难治性高血压)成人中降低血压的疗效和安全性得到证实。
  • 低钠血症、高钾血症和肾功能下降在lorundrostat组较安慰剂更常见,50 mg组因高钾血症停药2例(0.37%)、因低钠血症停药2例(0.37%)、因肾功能下降停药3例(0.56%)。

指南或共识出处

  • Launch-HTN随机临床试验,ClinicalTrials.gov注册号NCT06153693。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Uncontrolled hypertension remains a global health concern and dysregulated aldosterone production is a central mechanism. Lorundrostat, a novel aldosterone synthase inhibitor that reduces aldosterone production, demonstrated efficacy in participants with uncontrolled hypertension, including those with treatment-resistant hypertension.

OBJECTIVE: To evaluate the efficacy and safety of lorundrostat for lowering blood pressure (BP) when added to a prescribed regimen of 2 to 5 antihypertensive medications in adults with uncontrolled hypertension and treatment-resistant hypertension.

DESIGN, SETTING, AND PARTICIPANTS: In this phase 3, randomized clinical trial, adults with uncontrolled hypertension, including those with treatment-resistant hypertension, were enrolled between November 2023 and September 2024 at 159 clinic sites across 13 countries. The last date of follow-up was January 24, 2025.

INTERVENTION: Randomization ratio of 1:2:1 to 50 mg/d of lorundrostat for 6 weeks followed by 100 mg/d of lorundrostat for 6 weeks (n = 270) if they met prespecified criteria, 50 mg/d of lorundrostat for 12 weeks (n = 541), or daily placebo for 12 weeks (n = 272). The prespecified criteria included systolic BP of 130 mm Hg or greater, potassium level of 4.8 mmol/L or less, sodium level of 135 mmol/L or greater, an estimated glomerular filtration rate (eGFR) of greater than 45 mL/min/1.73 m2, and less than a 25% reduction in eGFR.

MAIN OUTCOME AND MEASURES: The primary outcome was change in automated office systolic BP at week 6 for participants randomized to 50 mg of lorundrostat vs placebo. Adverse events of special interest included dose reduction, interruption, or discontinuation due to events such as hyperkalemia, hyponatremia, and reduction in kidney function.

RESULTS: Of the 1083 participants, the mean age was 61.6 years (SD, 10.3 years), 508 (46.9%) were female, 311 (28.7%) were Black or African American, 733 (67.7%) were White, and 685 (63.3%) had a body mass index of 30 or greater (obesity). At randomization, 432 participants (39.9%) were taking 2 prescribed antihypertensive medications and 651 (60.1%) were taking 3 or more. For the pooled 50 mg of lorundrostat group (n = 808), the least-squares mean change in automated office systolic BP at week 6 was -16.9 mm Hg (95% CI, -19.0 to -14.9 mm Hg) vs -7.9 mm Hg (95% CI, -11.5 to -4.2 mm Hg) for the placebo group (least-squares mean difference, -9.1 mm Hg [95% CI, -13.3 to -4.9 mm Hg]; P < .001). Hyponatremia, hyperkalemia, and reduction in kidney function were reported more often with lorundrostat vs placebo. In the 50 mg of lorundrostat group with possible escalation to 100 mg, treatment discontinuation occurred in 1 participant (0.37%) due to hyperkalemia, in 1 (0.37%) due to hyponatremia, and in 0 due to reduction in kidney function. In the 50 mg of lorundrostat group, treatment discontinuation occurred in 2 participants (0.37%) due to hyperkalemia, in 2 (0.37%) due to hyponatremia, and in 3 (0.56%) due to reduction in kidney function. Treatment-emergent adverse events occurred in 49.9% of participants (538/1078) and were mostly mild or moderate in severity.

CONCLUSIONS AND RELEVANCE: The efficacy and safety of lorundrostat, an aldosterone synthase inhibitor, was demonstrated for lowering BP in adults with uncontrolled hypertension, including those with treatment-resistant hypertension.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06153693.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Saxena M, Laffin L, Borghi C, et al. Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial. JAMA. 2025. PMID: 40587141. doi:10.1001/jama.2025.9413

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。